GCAR is a 501(c)(3) non-profit corporation pioneering collaborative, innovative clinical trials to speed the discovery and development of cures
Larkspur, CA
Joined October 2017
- Tweets873
- Following1K
- Followers1K
- Likes2.6K
What does it take to rethink how new therapies are evaluated for glioblastoma?
In a new conversation from GCAR, leaders in neuro-oncology and clinical research share their perspectives on GBM AGILE and how an adaptive platform trial can create a more efficient, continuously learning approach to evaluating potential therapies for GBM.
Featuring insights from:
- Meredith Buxton, PhD, MPH - Global Coalition for Adaptive Research
- Tim Cloughesy, MD - University of California Los Angeles and Global Coalition for Adaptive Research
- Patrick Y. Wen, MD - Mass General Brigham
- Michael Weller, MD - University Hospital Zurich
- John de Groot, MD - University of California San Francisco
- Macarena de la Fuente, MD - University of Miami
With the neuro-oncology community preparing to gather at #SNO2026, the conversation is particularly timely: how can GBM AGILE help us learn faster and improve the way potential new therapies are evaluated in glioblastoma?
Watch the full conversation: gcaresearch.org/educational-…
#GBMAGILE #Glioblastoma #NeuroOncology #ClinicalTrials #AdaptiveTrials #SNO2026
GBM AGILE clinical leadership together at EANO 2026.
Behind GBM AGILE is a global network of leading experts in neuro-oncology, clinical research, and innovative trial design - working together to advance the evaluation of investigational therapies for glioblastoma.
For pharma and biotech companies developing therapies for GBM, the platform combines deep clinical and scientific expertise with an established global adaptive platform trial infrastructure.
EANO is always a valuable opportunity to connect with colleagues across the field, exchange ideas, and explore new opportunities to collaborate.
To learn more about bringing your investigational therapy into GBM AGILE – email [email protected]
Photo: Drs. Erik Sulman @ErikSulman , Timothy Cloughesy @TCloughesy, Andrew Lassman, Macarena De la Fuente @delaFuenteNOnc, and John de Groot @J_deGrootMD .
#EANO2026 #GBMAGILE #Glioblastoma #NeuroOncology #DrugDevelopment #ClinicalTrials #AdaptiveTrials
On #RareCancerDay, we recognize the individuals, families, researchers, clinicians, and advocates working to drive progress for cancers that can be especially challenging to treat and study.
At GCAR, our collaborations through innovative platform trials are helping create new approaches to clinical research in several rare cancers:
• GBM AGILE | Glioblastoma
• ARBOR BTC | Biliary Tract Cancer
• LGSOC Platform Trial | Low-Grade Serous Ovarian Cancer
When patient populations are small, bringing together disease experts, advocacy organizations, researchers, and industry - and designing trials to learn efficiently – becomes critically important.
We’re proud to work alongside these communities to help advance research and expand opportunities to evaluate new therapies.
To learn more about GCAR’s clinical trials visit: GCAResearch.org
#RareCancerDay #RareCancers #ClinicalTrials #AdaptiveTrials #OncologyResearch
GCAR was pleased to join the National Brain Tumor Society (NBTS) @NBTStweets Research Roundtable for an important discussion about clinical trials.
Conversations like these bring together perspectives from across the brain tumor community to address the challenges of clinical development & research, and explore opportunities to improve how new therapies are evaluated for patients.
Through GBM AGILE, GCAR and NBTS have a longstanding partnership grounded in a shared commitment to advancing progress for people affected by glioblastoma. We’re grateful for opportunities like the Research Roundtable to learn from one another, strengthen collaboration, and continue working together toward better options for patients.
Photo: Rob Murray, Chief Business and Strategy Officer, GCAR, @TCloughesy, Chief Medical Officer and Global PI GBM AGILE, GCAR, and @J_deGrootMD, GBM AGILE Arm Selection Committee Member.
#GBMAGILE #Glioblastoma #GBM #ClinicalTrials #ClinicalResearch #BrainTumorResearch #Collaboration
September is Ovarian Cancer Awareness Month - a time to raise awareness and highlight the continued need for research and new treatment options.
At GCAR, we’re advancing innovative clinical trials across distinct forms of ovarian cancer:
Ovarian CanceRx - High-Grade Ovarian Cancer
LGSOC Platform Trial - Low-Grade Serous Ovarian Cancer
While these cancers differ in important ways, both trials bring together disease experts, researchers, advocacy organizations, and industry around a shared goal: creating more efficient approaches to evaluating new therapies and advancing ovarian cancer research.
Developing a therapy for ovarian cancer? Connect with GCAR to explore opportunities to collaborate and how our innovative trial designs can help accelerate and streamline clinical development.
To learn more email [email protected]
#OvarianCancerAwarenessMonth #OvarianCancer #LGSOC #ClinicalTrials #AdaptiveTrials #OncologyResearch
Seven years ago, GBM AGILE set out to change how therapies for glioblastoma are developed.
Today, that vision continues to gain momentum:
• More than 2,600 patients have enrolled in study screening.
• The platform has demonstrated its ability to evaluate therapies more efficiently while maintaining scientific rigor.
• An eighth investigational arm is now active, expanding opportunities to learn faster and accelerate the development of potential new treatments.
None of this would be possible without the patients, caregivers, investigators, research sites, industry partners, advocates, and other collaborators who continue to make GBM AGILE possible.
In her latest letter, GCAR’s CEO & President Meredith Buxton reflects on seven years of progress, collaboration, and continued work as we remain committed to challenging convention and accelerating progress for patients.
#GBMAGILE #Glioblastoma #GBM #ClinicalTrial #AdaptiveTrial #PlatformTrial #ClinicalResearch #BrainTumor #ResearchInnovation
Global Coalition for Adaptive Research retweeted
We’re thankful to partner with @GCAResearch in support of #GBMDay.
Through this collaboration, we aim to continue providing better access to treatments and advancements in glioblastoma research.
Learn how you can take action at: BrainTumor.org/GBMDay
Five days.
That's all it took to go from first site activated to first patient randomized.
This milestone reflects what's possible when clinical trials are designed as systems of continuous learning. Instead of building a new trial for every question or investigational therapy, GBM AGILE efficiently reduces timelines to learn faster - accelerating the path from discovery to patient impact.
The first patients have been randomized and dosed to the tinostamustine arm on GBM AGILE, marking an important step forward for patients and the future of more efficient clinical research.
Read the announcement: gcaresearch.org/news/knoa-ph…
#GBMAGILE #Glioblastoma #GBM #ClinicalTrial #MasterProtocol #PlatformTrial #Adaptive
GBM AGILE leadership gathering at #ASCO26
Trial leadership met to discuss innovative design enhancements and identify opportunities to further improve operational efficiency while maintaining scientific rigor and maximizing learning. 🔎
Since launching in 2019, eight investigational therapies have entered the trial. Sites in six countries on three continents have screened over 2700 patients. 🌏
In other recent highlights: Primary analysis of regorafenib was published in JCO in April.
Thank you trial leadership for your dedication to accelerating the discovery, evaluation, and development of new treatment options for patients with #glioblastoma. 🧠
We are #FasterTogether! 🙌
#GBMAGILE
GCAR’s CEO/President, Meredith Buxton, and Chief Business and Strategy Officer, Rob Murray, catching up with Diane Simeone @MadameSurgeon, member of the IMPACT PDAC leadership council at #ASCO26.
IMPACT PDAC (Innovative Master Protocol to Accelerate Clinical Therapeutics for Pancreatic Ductal Adenocarcinoma) is the next phase in a groundbreaking effort to advance new treatments for pancreatic cancer. This new master protocol is sponsored by GCAR and builds on a strategic alliance with @PanCAN .
To learn more about this forthcoming, groundbreaking trial, visit: gcaresearch.org/research/imp…
We’re honored to partner with the @CCAlliance to launch KLEOS - a ground-breaking step toward changing how colorectal cancer therapies are developed and evaluated.
By combining the Alliance’s leadership and compassion with GCAR’s expertise in adaptive platform trials, we’re building a more efficient, collaborative, and truly patient-centered path to discovery.
This work can accelerate learning, reduce barriers, and bring promising treatments to patients sooner. We’re deeply grateful to the patients, advocates, clinicians, and researchers making this possible. Excited and inspired by what lies ahead!
#KLEOS #ColorectalCancer #ClinicalTrial #AccelerateLearning
If you or someone you love has colorectal cancer, you know the hardest part isn't just the diagnosis — it's the waiting. Waiting for new treatments that take too long. Waiting for something better.
Today at the Annual Meeting of the American Society of Clinical Oncology, we're letting everyone know we're going to fix that.
The Colorectal Cancer Alliance is unveiling KLEOS — a bold new initiative to transform how colorectal cancer treatments are developed and approved. Backed by nearly $7.5 million in seed donations and a collaboration with the Global Coalition for Adaptive Research, KLEOS will create a smarter, faster way to test new cancer therapies.
Here's what that means for patients:
✅ More treatment options, developed faster
✅ Less time lost on drugs that don't work
✅ A future where a colorectal cancer diagnosis comes with better answers
We're building this now. The first patients are expected to enroll in early 2027, and the treatments that follow will change what it means to be diagnosed with colorectal cancer.
KLEOS is named after the ancient Greek word for glory — for the legacy of everyone we've lost to this disease. It exists because of donors, researchers, and patients who refused to accept the status quo.
Learn more 👉 bit.ly/KLEOS-Announcement
If you need support right now, including help navigating clinical trials that exist today, our cancer care team is here for you. Call us at (877) 422-2030.
Global Coalition for Adaptive Research retweeted
The newly seated Project Cure CRC Consortium, assembled to guide the Alliance's work toward cures, got its first look at KLEOS at the ASCO annual meeting in Chicago. The Alliance's adaptive clinical trial platform was the focus of a panel featuring Alliance CEO Michael Sapienza and Dr. Meredith Buxton, CEO of the Global Coalition for Adaptive Research, among other oncology leaders. Panelists discussed KLEOS's vast potential and urgent goal to bring new treatments to patients faster.
Learn more about KLEOS: bit.ly/KLEOS-Announcement
#ASCO26 @ASCO
We are thrilled to announce a collaboration with the Colorectal Cancer Alliance @CCAlliance to advance a groundbreaking adaptive clinical trial platform for colorectal cancer: KLEOS
To read the full announcement, visit: gcaresearch.org/news/colorec…
#ColorectalCancer #ClinicalTrial #AdaptiveTrial #KLEOS
May is Neurofibromatosis Awareness Month.
Advancing therapies for rare diseases like NF requires bold new approaches. GCAR, with the @ChildrensTumor Foundation, is powering a first‑of‑its‑kind adaptive platform trial to efficiently evaluate investigational therapies across key NF1 manifestations.
For pharma and biotech partners, this model streamlines evidence generation, shortens development timelines, and speeds critical decisions - bringing potential treatments to patients faster.
Join us in accelerating progress for people with NF.
Email [email protected] to learn more.
#NeurofibromatosisAwarenessMonth #NFawareness #EndNF #Neurofibromatosis #NF1 #NFResearch
Want a smarter, faster path for your oncology asset?
Explore GCAR’s cutting-edge master protocols across glioblastoma, pancreatic, biliary tract, and ovarian cancers.
Connect with our team at #ASCO2026
📩 Email us to schedule a meeting – [email protected]
#ClinicalResearch #ClinicalTrials #PlatformTrials #MasterProtocol #AdaptiveTrials
GCAR is accelerating a portfolio of collaborative master protocols across glioblastoma, pancreatic, biliary tract, and ovarian cancers. Our adaptive platforms speed evaluation of promising therapies.
Have an oncology asset? Let’s connect at #ASCO26 to explore platform trial opportunities.
📩 Email us to schedule a meeting – [email protected]
#ClinicalResearch #ClinicalTrials #PlatformTrials #Adaptive #Oncology
Today, on International Clinical Trials Day, we recognize that clinical research is a truly global endeavor. Progress in medicine depends on collaboration - bringing together patients, investigators, institutions, industry partners, and advocates from around the world with a shared commitment to advancing science and improving lives.
At GCAR, we are proud to contribute to multinational partnerships and global learning networks that accelerate research, expand access to innovation, and generate knowledge that benefits patients everywhere.
Thank you to every patient, caregiver, researcher, clinician, coordinator, and partner helping move clinical research forward together.
#InternationalClinicalTrialsDay #ClinicalResearch #GlobalCollaboration #Innovation #ClinicalTrials
We had the privilege of welcoming @melinda_bachini, Chief Patient Officer of the Cholangiocarcinoma Foundation @curecc, to speak with our team about her passion for patient advocacy. Drawing on her personal experience, she offers valuable insight into the patient viewpoint in clinical trials.
A 16-year survivor of cholangiocarcinoma, Melinda shared powerful perspectives that serve as an important reminder of the real-world impact of clinical research - and the patients at the center of it.
Through our collaboration with the Cholangiocarcinoma Foundation and disease experts, we are developing ARBOR BTC, an innovative platform trial to advance new options for patients with biliary tract cancer. At GCAR, we are committed to making clinical trials more efficient and accelerating the discovery and development of new therapies.
We’re deeply grateful to Melinda for sharing her story and for her continued leadership in the patient advocacy community. 💚
Tomorrow is International Clinical Trials Day – a day to recognize the vital role of clinical research in advancing new treatment options for patients.
At GCAR, we are proud to be pioneering progress through a portfolio of innovative platform trials across glioblastoma, posttraumatic stress disorder, ovarian cancer, biliary tract cancer, neurofibromatosis, and pancreatic cancer - working to evaluate therapies more efficiently and expand access to promising options.
Together with our partners, we’re helping shape a more collaborative, patient-centered future for clinical trials.
#CTD2026 #ClinicalTrialsDay #FasterTogether
The “GCAR Glioma Getters” Team joined the National Brain Tumor Society’s Brain Tumor Walk & Race in Los Angeles, while GCAR staff, family, and friends across the country participated remotely to show nationwide support. 🧠🙌
GCAR was proud to participate; Rachel Rosenstein‑Sisson spoke at the Southern California event alongside patients, caregivers, advocates, and supporters united in advancing progress for those affected by brain tumors.
Thank you to NBTS for an inspiring, meaningful day. Together we’ll keep pushing for better treatments and brighter futures.
@NBTStweets
#BrainTumorAwareness #GoGrayInMay #Glioblastoma #GBMAGILE #ClinicalResearch #FasterTogether
